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Background: The latest World Health Organization guidelines
recommend replacing stavudine with tenofovir or zidovudine in ﬁrst-
line antiretroviral therapy in resource-limited settings. We report on
outcomes and toxicities among patients on these different regimens in
a routine treatment cohort in Lesotho.
Methods: All adult patients initiating antiretroviral therapy from
January 1, 2008, to December 31, 2008, were included in the analysis
and followed until December 31, 2009. Choice of regimen was
determined by clinical criteria.
Results: Of 1124 patient records analyzed, median agewas 39 years,
and the majority (67.7%) were women. Five hundred eighty-seven
patients were started on tenofovir, 255 on zidovudine, and 282 on
stavudine. Patients on zidovudine were more than twice as likely to
experience a toxicity-driven regimen substitution compared with
tenofovir (adjusted hazard ratio: 2.32, 95% conﬁdence interval:
1.23 to 4.40); for patients on stavudine, the risk of a toxicity-driven
regimen switch was almost 6 times higher than tenofovir (adjusted
hazard ratio: 5.43, 95% conﬁdence interval: 3.31 to 8.91).
Conclusions: Our ﬁndings support the latest World Health
Organization Guidelines, in particular the adoption of tenofovir in
ﬁrst line, given the advantages in terms of tolerability and availability
as a once-daily formulation.
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INTRODUCTION
Antiretroviral therapy (ART) has transformed HIV
infection into a manageable, lifelong disease. Simple, potent,
and tolerable ﬁrst-line regimens are critical to successful ART
outcomes in the long term.
1 Currently, the most commonly
used backbone drug in resource-limited settings is stavudine,
a drug associated with a high rate of side-effects related to its
mitochondrial toxicity, including lactic acidosis, peripheral
neuropathy and lipodystrophy.
2 These side-effects have led to
stavudine use being abandoned in developed countries in
favour of less toxic alternatives, predominantly tenofovir
disoproxil fumarate (tenofovir).
3 Tenofovir exhibits lower rates
of side-effects,
4 and its long intracellular half-life allows for
formulation as a once-a-day regimen [together with lamivu-
dine or emtricitabine and efavirenz].
5 In randomized trials,
tenofovir has demonstrated comparable or greater efﬁcacy
compared with other ﬁrst-line regimens such as zidovudine,
stavudine, or abacavir.
6–8
For these reasons, the World Health Organization
(WHO) revised its guidelines for ART in late 2009 to
recommend phasing out of stavudine in resource-limited
settings,
9 and many countries in southern Africa are currently
revising their guidelines to replace stavudine with the WHO-
recommended alternatives of tenofovir or zidovudine. Before
these recommendations, only a few countries in Africa
(Zambia, Namibia, Lesotho, and Botswana) had adopted
tenofovir in ﬁrst line.
2 Thus there is a scarcity of reporting
of outcomes on tenofovir compared with other regimens in
low-resource settings.
In this article, we report on outcomes and toxicities
among patients on tenofovir, zidovudine, and stavudine-based
ﬁrst-line ART in a routine treatment cohort in Lesotho.
METHODS
Study Setting and Treatment Protocols
In 2006, Me ´decins Sans Frontie `res and the Ministry
of Health and Social Welfare established a decentralized
HIV/AIDS care and treatment program at the primary health
care level in Scott Health Service Area, Lesotho, serving
a population of approximately 200,000 people.
10 Lesotho
opted to implement a tenofovir-based ﬁrst-line regimen in late
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9 Tenofovir is prescribed to all nonpregnant adults aged
.18 years with adequate renal function (creatinine clearance
(CrCl .50 mL/min). Zidovudine is provided in case of
pregnancy or where CrCl is ,50mL/min; and stavudine for
those patients who are excluded from receiving zidovudine
(hemoglobin ,8 g/dL) or tenofovir. All regimens include
lamivudine and either nevirapine or efavirenz; those on
tenofovir were almost exclusively on efavirenz, whereas there
was an equal proportion on both nevirapine and efavirenz for
those initiated on zidovudine or stavudine. The 3 regimens
were used concurrently during the period of this analysis due
to the phased introduction of tenofovir while staff became
familiar with the new protocol.
Data Extraction and Analysis
All adult patients (.18 years) initiating ART from
January 1, 2008, to December 31, 2008, were included in the
analysis and followed until December 31, 2009. All toxicities
were noted in the patient ﬁles upon receipt of laboratory results
by clinicalstaff.Datawere extractedfrompatient ﬁlesby a team
of 3 clinicians, entered into an Access database, and exported
into STATA (version 11) for analysis. Patients with severe renal
insufﬁciency (CrCl ,30 mL/min) were removed from analysis
to avoid bias by baseline renal function. Descriptive analyses
were based on percentages and frequencies for categorical
variables and medians and interquartile ranges (IQR) for
continuous variables. We described probability of survival and
regimen switching among patients initiating ARTon tenofovir-
based, zidovudine-based, or stavudine-based regimens using
Nelson–Aalen cumulative hazards estimates and modelled the
risk of mortality, loss to follow-up, and toxicity-driven regimen
substitution using Cox regression adjusting for the following
confounders identiﬁed a priori: age (,40 and .40 years),
gender, tuberculosis at initiation, pregnancy at initiation,
baseline CD4 (#200 and .200 cells/mm
3 and baseline
creatinine (30–50 mL/minute, .50 mL/minute, and missing).
Endpoints were the time from ART initiation to (1) death, (2)
loss to follow-up or (3) ﬁrst toxicity-driven switch. Time was
censored at loss to follow-up (deﬁned as missing an
appointment for more than 90 days) and transfer for the
mortality analysis, death, and transfer for the loss to follow-up
analysis and for all 3 for the regimen substitution analysis. All
reported P values are exact and 2-tailed; and for each analysis,
a P value of ,0.05 was considered signiﬁcant.
The analysis was approved by Me ´decins Sans Frontie `res’s
independent Ethics Review Board.
RESULTS
Between January 01, 2008, and December 31, 2008,
1185 adult patients were enrolled into care according to the
national guidelines criteria for ART (CD4 ,350 or Stage III
and IV). Fourty-eight patients had no baseline CD4 and
13 patients had a baseline CrCl ,30 mL/min and were
excluded from further analysis. Of the 1124 patient records
carried through for analysis, median age was 39 years, and the
majority (761, 67.7%) were women. Five hundred eighty-
seven patients were started on a tenofovir-based regimen, 255
on an zidovudine-based regimen, and 282 on a stavudine-
based regimen. Median time on treatment was 483 days for
tenofovir (IQR: 392–585), 493 days for zidovudine (IQR:
349–580), and 480 days for stavudine (IQR: 277–610)
(Table 1). Fewer women were initiated on tenofovir (53.5%)
compared with zidovudine (89%) or stavudine (78%); this was
due to initial misconceptions among health providers that
tenofovir should not be prescribed to women of childbearing
age. Almost all women (98%) who were pregnant at initiation
were initiated on a zidovudine-based regimen. Almost all
patientsinitiated ona tenofovir-basedregimen (96.8%) received
a baseline renal function test; the proportion of patients with
a low baseline creatinine clearance (30–50 mL/min) was higher
for patients on zidovudine and stavudine, consistent with the
fact that low creatinine clearance was an exclusion criteria for
tenofovir administration.
The overall mortality rate for the cohort was 6.5 per 100
person-years [conﬁdence interval (CI) 95%: 5.3 to 7.9 per
100 person-years], with a trend toward a higher mortality rate
among patients on non-tenofovir regimens: for those started on
tenofovir, the mortality rate was 5.1 per 100 person-years
(CI 95%: 3.8 to 7.0), compared with 7.5 per 100 person-years
for thosestartedonzidovudine(CI95%:5.0to11.1)and8.3per
100 person-years for those started on stavudine (CI 95%:5.8 to
11.7). In multivariate analysis comparing the risk of mortality,
there was a nonsigniﬁcant trend toward higher mortality among
patients on zidovudine [adjusted hazard ratio (aHR): 1.68, CI
95%: 0.88 to 3.21] or stavudine (aHR 1.40, CI 95%: 0.79 to
2.49) compared with tenofovir. Differences in loss to-follow up
were not statistically signiﬁcant.
The rate of toxicity-driven regimen substitutions overall
was 8.0 switches per 100 person-years (CI 95%: 6.7 to 9.6);
this rate differed signiﬁcantly according to drug regimen.
Patients on tenofovir switched at a rate of 3.0 switches per 100
patient-years (CI 95%: 2.0 to 4.5) compared with 8.1 switches
per 100 patient-years for zidovudine (CI 95%: 5.4 to 12.1) and
18.8 switches per 100 patient-years for stavudine (CI 95%:
14.8 to 24.1) (Fig. 1.) In multivariate analysis, patients on
zidovudine were more than twice as likely to experience
a toxicity requiring a regimen substitution compared with
those on tenofovir (aHR: 2.32, 95% CI: 1.23 to 4.40); for
patients on stavudine, the risk of a toxicity-driven regimen
switch was almost 6 times higher compared with tenofovir
(aHR: 5.43, 95% CI: 3.31 to 8.91). Among patients on
tenofovir experiencing a toxicity requiring a regimen change
(n = 19), the most common reason for switching was renal
toxicity (18 patients). For zidovudine (n = 15), it was severe
anemia (11 patients). For stavudine (n = 42), it was severe
neuropathy (29 patients) and lipodystrophy (11 patients);
2 patients had severe lactic acidosis.
DISCUSSION
In this nurse-managed community cohort, tenofovir was
found to be associated with substantially lower rate of toxicity-
driven regimen substitution compared with zidovudine and
stavudine, consistent with other published reports.
11 Therewas
also a tendency toward improved survival, but this did not
reach statistical signiﬁcance. Tenofovir-associated renal
toxicity was low: of the 5% who developed toxicity, the
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but 3 returned to normal on a subsequent measurement. This
lower toxicity is particularly important for settings where
detection of lactic acidosis is difﬁcult (lactic acidosis was
likely underestimated in our cohort for this reason), and
monitoring of neuropathy and lipodystrophy is clinically
challenging. Where access to routine laboratory monitoring is
a challenge and human resources are scarce, the use of
antiretrovirals with a lower risk of side-effects is supportive of
a public health approach to delivering ART.
12 Reducing
regimen switches is also desirable to maximize adherence
13
and preserve drug options for the management of treatment
failure.
14
Our analysis is based on programatic data in which
treatment was allocated for clinical reasons, prescriber
preference, or drug availability. Important differences in baseline
characteristics were observed, and we attempted to adjust for
confounding that may have resulted from prescribing bias
(notably differences in baseline renal function, gender, and
pregnancy status) but cannot rule out residual confounding. The
NNRTI component may have contributed to a degree of toxicity;
however, this is unlikely to be an important source of bias as
reported rates of toxicity associated with efavirenz and nevirapine
are far lower than for stavudine and zidovudine.
11
In conclusion, our results provide further evidence that
a tenofovir-based ﬁrst-line regimen is supportive of simpliﬁed
care by reducing the rate of regimen substitutions compared
with stavudine-based and zidovudine-based regimens. These
ﬁndings are encouraging for developing country governments
currently considering implementation of the new WHO
guidelines, in particular, the introduction of tenofovir as
a preferred ﬁrst-line option, given the advantages over
zidovudine in terms of ease-of-use and availability as
a once-daily formulation.
ACKNOWLEDGMENTS
We would like to thank Rachel Cohen, Sharonann Lynch,
Prinitha Pillay, and Peter Saranchuk for their essential
contributions in the establishment and evolution of the
treatment program.
REFERENCES
1. Stone VE. Strategies for optimizing adherence to highly active
antiretroviral therapy: lessons from research and clinical practice. Clin
Infect Dis. 200115;33:865–872.
2. Ford N, Calmy A. Improving ﬁrst-line antiretroviral therapy in resource-
limited settings. Current Opin HIVAIDS. 2010;5:38–47.
3. Brinkman K. Stavudine in antiretroviral therapy: is this the end? AIDS.
2009;23:1727–1729.
TABLE 1. Characteristics of Patients According to Treatment Regimen
Total Patients (n = 1124) Tenofovir, (n = 587) Zidovudine, (n = 255) Stavudine, (n = 282)
CD4, median (IQR)* 211 (119–284) 212 (119–283) 233 (149–303) 185 (95–267)
Time on ART (days), median (IQR) 485 (369–587) 483 (392–585) 493 (349–580) 480 (277–610)
Female, n (%) 761 (67.7%) 314 (53.5%) 227 (89.0%) 220 (78.0%)
Age, median (IQR) 39.0 (30.8–49.2) 39.3 (32.4–48.4) 34.3 (28.4–46.2) 42.3 (32.1–53.5)
Pregnant at initiation†
No 1044 (93.0%) 313 (99.8%) 149 (65.6%) 219 (99.6%)
Yes 80 (7.0%) 1 (0.2%) 78 (34.4%) 1 (0.4%)
Backbone regimen
Nevirapine 290 (25.8%) 1 (0.2%) 134 (52.5%) 155 (55.0%)
Efavirenz 816 (74.2%) 568 (99.8%) 121 (47.5%) 127 (45.0%)
Prior tuberculosis
No 952 (83.8%) 481 (81.9%) 227 (88.3%) 244 (83.6%)
Yes 184 (16.2%) 106 (18.1%) 30 (11.7%) 48 (16.4%)
Baseline creatinine
30–50 mL/min 160 (14.2%) 17 (2.9%) 47 (18.4%) 96 (34.2%)
.50 mL/min 775 (69.0%) 551 (93.9%) 115 (45.1%) 109 (38.8%)
Missing 189 (16.8%) 19 (3.2%) 93 (36.5%) 77 (27.1%)
*Data missing for 59 patients.
†Denominator includes only women.
FIGURE 1. Cumulative hazard estimates for toxicity driven
regimen change.
q 2011 Lippincott Williams & Wilkins www.jaids.com | e77
J Acquir Immune Deﬁc Syndr   Volume 56, Number 3, March 1, 2011 Implementing a Tenofovir-Based First-Line Regimen4. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity
in human cells treated with tenofovir: comparison with other nucleoside
reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2002;46:
716–723.
5. Grim SA, Romanelli F. Tenofovir disoproxil fumarate. Ann pharmacother.
2003;37:849–859.
6. Gallant JE, Staszewski S, Pozniak AL, et al. Efﬁcacy and safety of
tenofovir DF vs stavudine in combination therapy in antiretroviral-naive
patients: a 3-year randomized trial. JAMA. 2004;292:191–201.
7. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and
efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J
Med. 2006;354:251–260.
8. Pozniak A. Tenofovir: whathave over1 millionyearsof patient experience
taught us? Int J Clin Pract. 2008;62:1285–1293.
9. Anon. Rapid Advice: Antiretroviral Therapy for HIV Infection in Adults
and Adolescents. Geneva, Switzerland: World Health Organization; 2009.
10. Cohen R, Lynch S, Bygrave H, et al. Antiretroviral treatment outcomes
from a nurse-driven, community-supported HIV/AIDS treatment pro-
gramme in rural Lesotho: observational cohort assessment at two years.
J Int AIDS Soc. 2009;12:23.
11. Davidson I, Beardsell H, Smith B, et al. The frequency and reasons for
antiretroviral switching with speciﬁc antiretroviral associations: the
SWITCH study. Antiviral Res. 2010;86:227–229.
12. Callaghan M, Ford N, Schneider H. A systematic reviewof task—shifting
for HIV treatment and care in Africa. Hum Resour Health. 2010;8:8.
13. Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART:
a systematic review of developed and developing nation patient-reported
barriers and facilitators. PLoS Med. 2006;3:e438.
14. Hawkins C, Achenbach C, Fryda W, et al. Antiretroviral durability
and tolerability in HIV-infected adults living in urban Kenya.
Journal of acquired immune deﬁciency syndromes (1999). 2007;45:
304–310.
e78 | www.jaids.com q 2011 Lippincott Williams & Wilkins
Bygrave et al J Acquir Immune Deﬁc Syndr   Volume 56, Number 3, March 1, 2011